A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates

The current unprecedented outbreak of Ebola virus (EBOV) disease in West Africa has demonstrated the urgent need for a vaccine. Here, we describe the evaluation of an EBOV vaccine candidate based on Kunjin replicon virus-like particles (KUN VLPs) encoding EBOV glycoprotein with a D637L mutation (GP/...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2015-10, Vol.212 (suppl 2), p.S368-S371
Main Authors: Pyankov, Oleg V., Bodnev, Sergey A., Pyankova, Olga G., Solodkyi, Vladislav V., Pyankov, Stepan A., Setoh, Yin Xiang, Volchkova, Valentina A., Suhrbier, Andreas, Volchkov, Viktor V., Agafonov, Alexander A., Khromykh, Alexander A.
Format: Article
Language:English
Subjects:
Africa, Western
Animals
Bacteriology
Cercopithecus aethiops
Ebola and Marburg Viruses-Research, Outbreak Management, Epidemiology and Ecology
Ebola Vaccines - immunology
Ebola virus
Ebolavirus - immunology
Glycoproteins - immunology
Hemorrhagic Fever, Ebola - immunology
Immunization - methods
Immunology
Life Sciences
Microbiology and Parasitology
Primates
Replicon - immunology
VACCINE/TREATMENT
Vaccines, Virus-Like Particle - immunology
Viral Proteins - immunology
Virology
West Nile virus - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The current unprecedented outbreak of Ebola virus (EBOV) disease in West Africa has demonstrated the urgent need for a vaccine. Here, we describe the evaluation of an EBOV vaccine candidate based on Kunjin replicon virus-like particles (KUN VLPs) encoding EBOV glycoprotein with a D637L mutation (GP/D637L) in nonhuman primates. Four African green monkeys (Cercopithecus aethiops) were injected subcutaneously with a dose of 10⁹ KUN VLPs per animal twice with an interval of 4 weeks, and animals were challenged 3 weeks later intramuscularly with 600 plaque-forming units of Zaire EBOV. Three animals were completely protected against EBOV challenge, while one vaccinated animal and the control animal died from infection. We suggest that KUN VLPs encoding GP/D637L represent a viable EBOV vaccine candidate.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiv019